Skip to content
EvidenceHelixEvidenceLib · Scientific Encyclopedia
⌘ K

Scientific library

EvidenceLib encyclopediaAll articles A–Z2,835
Books209
All textbooksMedical textbooksHuman anatomyOrganisms & biodiversityOther sciences
Open-access articles1,406Cancer study catalog458How it is made

My workspace this browser

Saved pages0Notes & annotations0

Recently viewed

Explore by field

Cancer and Oncology182Genetics and Genomics170Neuroscience185Cardiovascular Medicine180Immunology142Pharmacology173Molecular Biology161Infectious Diseases150Rare and Inherited Diseases181Clinical Research173Anatomy and Physiology613Drugs and Chemicals621Psychiatry and Psychology185Public Health and Nutrition178Diagnostics and Medical Technology125Respiratory Medicine113Digestive System and Liver91Metabolism and Endocrine Disease177Bones, Joints, Muscles and Skin213Kidney, Urology and Women's Health173Eye, Ear, Nose and Throat55
Plans & pricingCompare EvidenceHelix workspace plans
Library›Open textbooks›Magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn’s disease: the METRIC-EF multivariable prediction model, multicentre diagnostic inception cohort study›References

Continue where you left off ()

GO BEYOND THE PAGEReading is just the beginning.

Turn scientific reading into research. Compare studies, examine evidence, and organize your findings in EvidenceHelix Workspace.

Explore Research Workspace →

Magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn’s disease: the METRIC-EF multivariable prediction model, multicentre diagnostic inception cohort study · References

References

CC BY 4.0 · National Institute for Health and Care Research · approximately 12 min read

  1. Kumar S, Plumb A, Mallett S, Bhatnagar G, Bloom S, Clarke CS, et al. METRIC-EF: magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn’s disease-protocol for a multicentre, non-randomised, single-arm, prospective study. BMJ Open 2022;12:e067265. 10.1136/bmjopen-2022-067265
  2. Ananthakrishnan AN, Nguyen GC, Bernstein CN. AGA clinical practice update on management of inflammatory bowel disease in elderly patients: expert review. Gastroenterology 2021;160:445–51.33011177
  3. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, et al.; IBD Guidelines eDelphi Consensus Group. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019;68:s1–106.31562236
  4. Lopes EW, Lochhead P, Burke KE, Richter JM, Ananthakrishnan AN, Chan AT, Khalili H. Risk factors for incident inflammatory bowel disease according to disease phenotype. Clin Gastroenterol Hepatol 2022;20:2347–57.e14.35031525
  5. Rogler G, Singh A, Kavanaugh A, Rubin DT. Extraintestinal manifestations of inflammatory bowel disease: current concepts, treatment, and implications for disease management. Gastroenterology 2021;161:1118–32.34358489
  6. Kumar S, Pollok R, Goldsmith D. Renal and urological disorders associated with inflammatory bowel disease. Inflamm Bowel Dis 2022;29:1306–16.
  7. Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al.; ECCO. 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis 2017;11:3–25.27660341
  8. Peyrin-Biroulet L, Loftus EV Jr, Colombel JF, Sandborn WJ. The natural history of adult Crohn’s disease in population-based cohorts. Am J Gastroenterol 2010;105:289–97.19861953
  9. Thia KT, Sandborn WJ, Harmsen WS, Zinsmeister AR, Loftus EV. Risk factors associated with progression to intestinal complications of Crohn’s disease in a population-based cohort. Gastroenterology 2010;139:1147–55.20637205
  10. GBD 2017 Inflammatory Bowel Disease Collaborators. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol 2020;5:17–30.31648971
  11. Ghosh N, Premchand P. A UK cost of care model for inflammatory bowel disease. Frontline Gastroenterol 2015;6:169–74.28839807
  12. Bassi A, Dodd S, Williamson P, Bodger K. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut 2004;53:1471–8.15361497
  13. Dignass A, Van Assche G, Lindsay JO, Lémann M, Söderholm J, Colombel JF, et al.; European Crohn’s and Colitis Organisation (ECCO). The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohns Colitis 2010;4:28–62.21122489
  14. Lichtenstein GR, Hanauer SB, Sandborn WJ; Practice Parameters Committee of American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465–83; quiz 464, 484.19174807
  15. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010;105:162–9.19755969
  16. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014;63:88–95.23974954
  17. Khanna R, Bressler B, Levesque BG, Zou G, Stitt LW, Greenberg GR, et al.; REACT Study Investigators. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet 2015;386:1825–34.26342731
  18. Colombel JF, Panaccione R, Bossuyt P, Lukas M, Baert F, Vaňásek T, et al. Effect of tight control management on Crohn’s disease (CALM): a multicentre, randomised, controlled phase 3 trial. Lancet 2017;390:2779–89.29096949
  19. Noor NM, Lee JC, Bond S, Dowling F, Brezina B, Patel KV, et al. A biomarker-stratified comparison of top-down versus accelerated step-up treatment: strategies for patients with newly diagnosed Crohn’s disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol 2024;9:e000347.
  20. Cushing K, Higgins PDR. Management of Crohn disease: a review. JAMA 2021;325:69–80.33399844
  21. Lichtenstein GR, Yan S, Bala M, Blank M, Sands BE. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn’s disease. Gastroenterology 2005;128:862–9.15825070
  22. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn’s disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008;6:644–53.18550004
  23. Peyrin-Biroulet L, Panes J, Sandborn WJ, Vermeire S, Danese S, Feagan BG, et al. Defining disease severity in inflammatory bowel diseases: current and future directions. Clin Gastroenterol Hepatol 2016;14:348–54.e17.26071941
  24. Loly C, Belaiche J, Louis E. Predictors of severe Crohn’s disease. Scand J Gastroenterol 2008;43:948–54.19086165
  25. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn’s disease. Gastroenterology 2006;130:650–6.16530505
  26. Yang CH, Ding J, Gao Y, Chen X, Yang ZB, Xiao SD. Risk factors that predict the requirement of aggressive therapy among Chinese patients with Crohn’s disease. J Dig Dis 2011;12:99–104.21401894
  27. Magro F, Estevinho MM, Catalano G, Patita M, Arroja B, Lago P, et al.; GEDII (Grupo de Estudos da Doença Inflamatória Intestinal). How many biomarker measurements are needed to predict prognosis in Crohn’s disease patients under infliximab? A prospective study. United European Gastroenterol J 2023;11:531–41.
  28. Noor NM, Verstockt B, Parkes M, Lee JC. Personalised medicine in Crohn’s disease. Lancet Gastroenterol Hepatol 2020;5:80–92.31818474
  29. Vermeire S, Ferrante M, Rutgeerts P. Recent advances: personalised use of current Crohn’s disease therapeutic options. Gut 2013;62:1511–5.24037876
  30. Rimola J, Torres J, Kumar S, Taylor SA, Kucharzik T. Recent advances in clinical practice: advances in cross-sectional imaging in inflammatory bowel disease. Gut 2022;71:2587–97.35927032
  31. Kumar S, Hakim A, Alexakis C, Chhaya V, Tzias D, Pilcher J, et al. Small intestinal contrast ultrasonography for the detection of small bowel complications in Crohn’s disease: correlation with intraoperative findings and magnetic resonance enterography. J Gastroenterol Hepatol 2015;30:86–91.25168482
  32. Kumar S, De Kock I, Blad W, Hare R, Pollok R, Taylor SA. Magnetic resonance enterography and intestinal ultrasound for the assessment and monitoring of Crohn’s disease. J Crohns Colitis 2024;18:1450–63.38554104
  33. Hameed M, Kumar S, Taylor SA. How I do it: cross-sectional imaging in small-bowel Crohn disease and ulcerative colitis. Radiology 2025;314:e241452.39932413
  34. Rimola J, Ordas I, Rodriguez S, García-Bosch O, Aceituno M, Llach J, et al. Magnetic resonance imaging for evaluation of Crohn’s disease: validation of parameters of severity and quantitative index of activity. Inflamm Bowel Dis 2011;17:1759–68.21744431
  35. Taylor SA, Mallett S, Bhatnagar G, Baldwin-Cleland R, Bloom S, Gupta A, et al.; METRIC Study Investigators. Diagnostic accuracy of magnetic resonance enterography and small bowel ultrasound for the extent and activity of newly diagnosed and relapsed Crohn’s disease (METRIC): a multicentre trial. Lancet Gastroenterol Hepatol 2018;3:548–58.29914843
  36. Ordas I, Rimola J, Alfaro I, Rodríguez S, Castro-Poceiro J, Ramírez-Morros A, et al. Development and validation of a simplified magnetic resonance index of activity for Crohn’s disease. Gastroenterology 2019;157:432–9.e1.30953614
  37. Hanzel J, Jairath V, Ma C, Guizzetti L, Zou G, Santillan CS, et al. Responsiveness of magnetic resonance enterography indices for evaluation of luminal disease activity in Crohn’s disease. Clin Gastroenterol Hepatol 2022;20:2598–606.35149220
  38. Kumar S, Parry T, Mallett S, Bhatnagar G, Plumb A, Walsh S, et al. Diagnostic performance of magnetic resonance enterography disease activity indices compared with a histological reference standard for adult terminal ileal Crohn’s disease: experience from the METRIC trial. J Crohns Colitis 2022;16:1531–9.35481898
  39. Kumar S, Rao N, Bhagwanani A, Parry T, Hameed M, Rahman S, et al. Volumetric measurement of terminal ileal Crohn’s disease by magnetic resonance enterography: a feasibility study. Eur Radiol 2024;35:117–26.39028375
  40. Rao N, Kumar S, Taylor S, Plumb A. Diagnostic pathways in Crohn’s disease. Clin Radiol 2019;74:578–91.31005268
  41. Miles A, Bhatnagar G, Halligan S, Gupta A, Tolan D, Zealley I, Taylor SA; METRIC Investigators. Magnetic resonance enterography, small bowel ultrasound and colonoscopy to diagnose and stage Crohn’s disease: patient acceptability and perceived burden. Eur Radiol 2019;29:1083–93.30128615
  42. Guglielmo FF, Anupindi SA, Fletcher JG, Al-Hawary MM, Dillman JR, Grand DJ, et al. Small bowel Crohn disease at CT and MR enterography: imaging Atlas and glossary of terms. Radiographics 2020;40:354–75.31951512
  43. Halligan S, Boone D, Archer L, Ahmad T, Bloom S, Rodriguez-Justo M, et al. Prognostic biomarkers to identify patients likely to develop severe Crohn’s disease: a systematic review. Health Technol Assess 2021;25:1–66.
  44. Jauregui-Amezaga A, Rimola J, Ordas I, Rodríguez S, Ramírez-Morros A, Gallego M, et al. Value of endoscopy and MRI for predicting intestinal surgery in patients with Crohn’s disease in the era of biologics. Gut 2015;64:1397–402.25516418
  45. Fiorino G, Morin M, Bonovas S, Bonifacio C, Spinelli A, Germain A, et al. Prevalence of bowel damage assessed by cross-sectional imaging in early Crohn’s disease and its impact on disease outcome. J Crohns Colitis 2017;11:274–80.27799269
  46. Fernandez-Clotet A, Panes J, Ricart E, Castro-Poceiro J, Masamunt MC, Rodríguez S, et al. Predictors of bowel damage in the long-term progression of Crohn’s disease. World J Clin Cases 2022;10:12208–20.36483818
  47. Dane B, Qian K, Krieger R, Smereka P, Foster J, Huang C, et al. Correlation between imaging findings on outpatient MR enterography (MRE) in adult patients with Crohn disease and progression to surgery within 5 years. Abdom Radiol 2022;47:3424–35.
  48. Taylor SA, Kumar S, Parry T, Mallett S, Travis S, Raine T, et al. Magnetic resonance enterography to predict subsequent disabling Crohn's disease in newly diagnosed patients (METRIC-EF)-multivariable prediction model, multicentre diagnostic inception cohort. Eur Radiol 2025;35(11):7333–45. 10.1007/s00330-025-11636-840369265
  49. Taylor SA, Mallett S, Bhatnagar G, Morris S, Quinn L, Tomini F, et al. Magnetic resonance enterography compared with ultrasonography in newly diagnosed and relapsing Crohn’s disease patients: the METRIC diagnostic accuracy study. Health Technol Assess 2019;23:1–162.
  50. Taylor S, Mallett S, Bhatnagar G, Bloom S, Gupta A, Halligan S, et al. METRIC (MREnterography or ulTRasound in Crohn’s disease): a study protocol for a multicentre, non-randomised, single-arm, prospective comparison study of magnetic resonance enterography and small bowel ultrasound compared to a reference standard in those aged 16 and over. BMC Gastroenterol 2014;14:142.25110044
  51. Collins GS, Reitsma JB, Altman DG, Moons KGM. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ 2015;350:g7594.25569120
  52. Prezzi D, Bhatnagar G, Vega R, Makanyanga J, Halligan S, Taylor SA. Monitoring Crohn’s disease during anti-TNF-alpha therapy: validation of the magnetic resonance enterography global score (MEGS) against a combined clinical reference standard. Eur Radiol 2016;26:2107–17.26433956
  53. Makanyanga JC, Pendse D, Dikaios N, Bloom S, McCartney S, Helbren E, et al. Evaluation of Crohn’s disease activity: initial validation of a magnetic resonance enterography global score (MEGS) against faecal calprotectin. Eur Radiol 2014;24:277–87.24026620
  54. Jose SK, Simon B, Simon EG, Eapen A, John RA, Putta T, et al. Comparison of magnetic resonance enterography global score (MEGS) with indices of Crohn’s disease activity in South Asian population. Abdom Radiol 2022;47:547–53.
  55. Klang E, Amitai MM, Lahat A, Yablecovitch D, Avidan B, Neuman S, et al.; Israeli IBD Research Nucleus (IIRN). Capsule endoscopy validation of the magnetic enterography global score in patients with established Crohn’s disease. J Crohns Colitis 2017;12:313–20.
  56. Capozzi N, Ordas I, Fernandez-Clotet A, Castro-Poceiro J, Rodríguez S, Alfaro I, et al. Validation of the Simplified Magnetic Resonance Index of Activity [sMARIA] without gadolinium-enhanced sequences for Crohn’s disease. J Crohns Colitis 2020;14:1074–81.32080712
  57. Rimola J, Alvarez-Cofino A, Perez-Jeldres T, Ayuso C, Alfaro I, Rodríguez S, et al. Comparison of three magnetic resonance enterography indices for grading activity in Crohn’s disease. J Gastroenterol 2017;52:585–93.27599973
  58. Pariente B, Mary JY, Danese S, Chowers Y, De Cruz P, D'Haens G, et al. Development of the Lemann index to assess digestive tract damage in patients with Crohn’s disease. Gastroenterology 2015;148:52–63.e3.25241327
  59. Dias CC, Rodrigues PP, da Costa-Pereira A, Magro F. Clinical prognostic factors for disabling Crohn’s disease: a systematic review and meta-analysis. World J Gastroenterol 2013;19:3866–71.23840127
  60. Rabilloud ML, Bajeux E, Siproudhis L, Hamonic S, Pagenault M, Brochard C, et al. Long-term outcomes and predictors of disabling disease in a population-based cohort of patients with incident Crohn’s disease diagnosed between 1994 and 1997. Clin Res Hepatol Gastroenterol 2022;46:101974.35691599
  61. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.16698746
  62. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003;125:1508–30.14598268
  63. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Habbema JDF. Substantial effective sample sizes were required for external validation studies of predictive logistic regression models. J Clin Epidemiol 2005;58:475–83.15845334
  64. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol 1995;48:1503–10.8543964
  65. Riley RD, Debray TPA, Collins GS, Archer L, Ensor J, van Smeden M, Snell KIE. Minimum sample size for external validation of a clinical prediction model with a binary outcome. Stat Med 2021;40:4230–51.34031906
  66. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, Gendre JP. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002;8:244–50.12131607
  67. van Buuren S, Boshuizen HC, Knook DL. Multiple imputation of missing blood pressure covariates in survival analysis. Stat Med 1999;18:681–94.10204197
  68. National Institute for Health and Care Excellence. NICE Health Technology Evaluations: The Manual. Process and Methods (PMG36). URL: www.nice.org.uk/process/pmg36 (accessed 15 April 2025).
  69. NHS. 2020/21 National Cost Collection Data Publication. URL: www.england.nhs.uk/publication/2020-21-national-cost-collection-data-publication/ (accessed 15 April 2025).
  70. Jo C. Cost-of-illness studies: concepts, scopes, and methods. Clin Mol Hepatol 2014;20:327–37.25548737
  71. Molodecky NA, Soon IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology 2012;142:46–54.e42; quiz e30.22001864
  72. Byford S, Torgerson DJ, Raftery J. Economic note: cost of illness studies. BMJ 2000;320:1335.10807635
  73. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol 2018;113:481–517.29610508
  74. Maaser C, Sturm A, Vavricka SR, Kucharzik T, Fiorino G, Annese V, et al.; European Crohn’s and Colitis Organisation [ECCO] and the European Society of Gastrointestinal and Abdominal Radiology [ESGAR]. ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: initial diagnosis, monitoring of known IBD, detection of complications. J Crohns Colitis 2019;13:144–64.30137275
  75. Roseira J, Ventosa AR, de Sousa HT, Brito J. The new simplified MARIA score applies beyond clinical trials: a suitable clinical practice tool for Crohn’s disease that parallels a simple endoscopic index and fecal calprotectin. United European Gastroenterol J 2020;8:1208–16.
  76. Tao Y, Li H, Xu H, Tang W, Fan G, Yang X. Can the simplified magnetic resonance index of activity be used to evaluate the degree of activity in Crohn’s disease? BMC Gastroenterol 2021;21:409.34711180
  77. Klang E, Amitai MM, Lahat A, Yablecovitch D, Avidan B, Neuman S, et al.; Israeli IBD Research Nucleus (IIRN). Capsule endoscopy validation of the magnetic enterography global score in patients with established Crohn’s disease. J Crohns Colitis 2018;12:313–20.29182750
  78. Rimola J, Rodriguez S, Garcia-Bosch O, Ordás I, Ayala E, Aceituno M, et al. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn’s disease. Gut 2009;58:1113–20.19136510
  79. Kumar S, Parry T, Mallett S, Plumb A, Bhatnagar G, Beable R, et al.; METRIC Study Group. Diagnostic performance of sonographic activity scores for adult terminal ileal Crohn’s disease compared to magnetic resonance and histological reference standards: experience from the METRIC trial. Eur Radiol 2024;34:455–64.37526665
  80. Bhatnagar G, Mallett S, Quinn L, Beable R, Bungay H, Betts M, et al. Interobserver variation in the interpretation of magnetic resonance enterography in Crohn’s disease. Br J Radiol 2022;95:20210995.35195444
  81. Jensen MD, Ormstrup T, Vagn-Hansen C, Østergaard L, Rafaelsen SR. Interobserver and intermodality agreement for detection of small bowel Crohn’s disease with MR enterography and CT enterography. Inflamm Bowel Dis 2011;17:1081–8.21484959
  82. Schleder S, Pawlik M, Wiggermann P, Ott C, Fichtner-Feigl S, Müller-Wille R, et al. Interobserver agreement in MR enterography for diagnostic assessment in patients with Crohn’s disease. RoFo Fortschr Geb Rontgenstr Nuklearmed 2013;184:992–7.23893750
  83. Tielbeek JA, Makanyanga JC, Bipat S, Pendsé DA, Nio CY, Vos FM, et al. Grading Crohn disease activity with MRI: interobserver variability of MRI features, MRI scoring of severity, and correlation with Crohn disease endoscopic index of severity. AJR Am J Roentgenol 2013;201:1220–8.24261360
  84. Thompson NP, Fleming DM, Charlton J, Pounder RE, Wakefield AJ. Patients consulting with Crohn’s disease in primary care in England and Wales. Eur J Gastroenterol Hepatol 1998;10:1007–12.9895046
  85. Chew C, Albazaz R, Taylor SA; BSGAR Committee. Diversity and equity: a radiology society’s effort. Clin Radiol 2021;76:475–6.33883065
← DiscussionAdditional information →

Attribution. Shankar Kumar; Andrew Plumb; Sue Mallett; Caroline Clarke; Tom Parry; Jing Yi Jessica Weng et al. (2026). Magnetic resonance enterography to predict disabling disease in newly diagnosed Crohn’s disease: the METRIC-EF multivariable prediction model, multicentre diagnostic inception cohort study. National Institute for Health and Care Research. Copyright © 2026 Kumar et al. Licensed under CC BY 4.0. NCBI Bookshelf NBK621032. CC BY 4.0. Original source ↗. Text reproduced from the Bookshelf XML without changing wording; figures, images and supplements are not reproduced.

In this chapter Contents

  • References

Source

OpenStax source file ↗

Source record ↗

EvidenceLib is a research-education resource, not medical advice. It does not diagnose, prescribe or recommend starting, stopping or changing any treatment. Talk to a qualified clinician about your own situation. Methods, sources and licences · Rights and removal requests · Legal · Support